Your CDx Partner from Translational Research to Global Commercialization

We collaborate closely with our pharma partners to help accelerate access to treatment by ensuring companion diagnostic testing readiness in the relevant markets at launch.

You can depend on a team of proven, IVD-experienced project managers, highly qualified scientists, manufacturing, quality and regulatory experts. Our commercial team works with us in tandem, enabling us to move seamlessly through each phase - from R&D through clinical and commercialization. All teams have a deep understanding of the oncology testing landscape.

Together, we ensure that product design requirements reflect customer and market needs from an analytic performance, end-user and economic perspective.

See Our Latest CDx Partnerships

The expertise and global reach to support
your success

• Compliance with international regulations, filing and marketing
• Global launch strategies for the companion diagnostic
• Market access and reimbursement strategies
• KOL programs to drive market awareness and readiness for the diagnostic test
• Medical education programs and organizing lab staff training
• Direct sales force and distributor partner network, leveraging key relationships with
• MDx end users, pathologists, and purchasers globally to support your success

Advancing precision oncology requires effective biomarker testing and actionable insights that drive better patient outcomes. With next-generation sequencing (NGS) testing in your hospital, you can get the insights you need when you need them - in days, not weeks.

A spectrum of NGS
oncology solutions

In oncology clinical research, a single solution can never fit all the different interactions, samples, and tumors to be tested.

That's why we equip you with a whole spectrum of solutions for tumor profiling from FFPE tissue samples to liquid biopsy.

Making precision oncology
possible Together

Our streamlined end-to-end workflows, relevant test menus, and support are empowering laboratories around the world to adopt NGS and move precision oncology forward.

Multi-biomarker testing:
a new paradigm

Oncomine Dx Target Test was the first, and is still the only commercially distributable multiple biomarker CDx test based on NGS, which can be implemented in new laboratories around the world.

Click one of the icons below to download a PDF for your country.

Enabling global access to testing

Oncomine Dx Target Test (Next-Generation Sequencing) was approved by the FDA in 2017, followed by self-declaration and launch of a CE marked version in Europe and approval in South Korea in 2018, and by MHLW in Japan in 2019.

Have questions? Ask one of our NGS consultants.

If you or members of your care team have questions, our team is available to answer them.